ERBB2 and non-small cell lung carcinoma: Clinical trials of CAR-T therapy targeting mesothelin (MSLN) [24], epidermal growth factor receptor (EGFR) [25], human epidermal growth factor receptor 2 (HER2) [26], and carcinoembryonic antigen (CEA) [27] in NSCLC have been completed in recent years, but with disappointing results.